WHITE OAK, Md. — The House is set to take up a controversial “right-to-try” bill next week — and if it passes, the Food and Drug Administration will have to work harder to protect patients than it would if a different version of the legislation were advancing, Commissioner Scott Gottlieb told STAT in an interview.

Gottlieb’s comments, made at FDA headquarters on Thursday, indicate that one of President Trump’s top lieutenants believes Congress is moving forward with a bill that contains less of his agency’s input than an alternative version of the bill — a more recent, updated bill that passed the House in March but ultimately stalled in the Senate.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Nas, I do know what I’m talking about; I was involved with some compassionate use deliberations when I worked in the industry. There are some liability issues which are addressed in the Right to Try legislation, but the bigger concerns seem to be supply issues and fear about what will happen if a compassionate use patient dies. The FDA sometimes assumes that the deaths might be due to the drug, not the disease, and then requires additional studies. Such extra time and effort can result in a competitor getting the lucrative first-to-market position in a new class of drugs.

    However, my comment specifically addressed the onerous requirements of the FDA’s compassionate use program on doctors who might otherwise try to get an investigational drug for their patients. Even if Right to Try passes, I suspect many companies will hesitate to utilize it for fear that the FDA will be offended and punish them by dragging their feet at various steps of the approval process. However, in states where it has passed, some patients are already benefiting: https://goldwaterinstitute.org/article/texas-doctor-using-right-to-try-law-to-treat-cance/. Some lives will likely be saved by this legislation, even with the type of concerns that both of us have mentioned.

  • The FDA has some bad hombres working there who are protecting the HIV drug gravy train they have been harming society keeping the mist tested HIV vaccine Remune the Salk vaccine off the Market and a small biotech Immune Response Biopharna the commissioner works more on dying his jet black Elvis hair then helping bring Remune to market.

  • One of the reasons that Right to Try got started was that the FDA required physicians to spend an average of 100 hours filling out paperwork for a compassionate use exemption for their patients, which most doctors wouldn’t do. Even when they did, many of the applications weren’t approved until it was too late for the patients. That’s how the Abigail Alliance (http://abigail-alliance.org/), which sued the FDA on behalf of terminally ill cancer patients, got started. When Right to Try got to Congress, the FDA finally simplified the paperwork somewhat. I’d like to see STAT include “the other side of the story” when they report that the FDA approves 99% of the applications.

    • Mary,
      With all due respect that is nonesense the applications aren’t submitted because the pharma doesn’t want to provide the drug, the paperwork was onerous, 99% of a small amount is fake. No HIV vaccine access to Remune for patients you live in a bubble while the govt protects it’s piece if the drug pie keeping patients hooked on HIV drugs is profitiable for even the govt. Cancer isn’t the only access problem, it’s a liability issue, and no incentive to provide the drugs to patients outside of the clinical trial process. You don’t know what you are talking about period.

  • The government has no right to get involved in our very personal healthcare decisions. They are in fact the proven worse group to be involved in anything that has to do with healthcare as has been proven by the current idiots in congress.

Your daily dose of news in health and medicine

Privacy Policy